Abstract
The impact of various meditation interventions on modifying human health outcomes has been demonstrated at both cognitive and cellular levels. Preksha Dhyana (PD) meditation has previously shown effects on cognitive skills, transcriptome, and the DNA methylome in healthy, novice college students. In this study, we performed a cross-platform metabolomic and lipidomic analysis of serum samples collected from 38 healthy, meditation-naïve participants and five age-matched participants who served as controls. Serum samples were collected from both groups, at baseline (pre-meditation) and after an 8-week PD intervention. Analysis was conducted using capillary electrophoresis and reversed-phase liquid chromatography coupled to electrospray ionization-mass spectrometry, and higher serum concentration levels for four circulating metabolites, namely, hypoxanthine, oxoproline, choline, and cystine, were identified along with a series of lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE) species (LPC 20:0, LPC 18:0, LPC 18:1, LPC 16:0, LPE 18:0, LPE 18:1, and LPE 22:6), following the PD intervention that satisfied a Bonferroni correction (p < 0.05, FDR). Pathway enrichment analysis revealed that these metabolites and lipids are primarily associated with the purine degradation cycle, glycerophospholipid metabolism, and glutathione metabolism, which are critical for maintaining cellular energy balance, preserving membrane integrity, and protecting against oxidative stress. A multi-omics analysis with Data Integration Analysis for Biomarker discovery using Latent approaches for Omics studies (DIABLO) revealed positive and negative correlations between these metabolites/lipids, DNA methylated sites (DMSs), and cognitive outcomes (r > 0.5). Overall, our findings suggest that the wellbeing experienced after PD meditation might be associated with bioactive metabolites and lipids, which may also function as epigenetic modifiers regulating gene expression and biological pathways. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier NCT03779269.